Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
2.270
-0.110 (-4.62%)
Jun 1, 2026, 9:40 AM EDT - Market open
Compass Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Compass Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $8.82. The average 1-year stock price forecast is 288.55% higher than the current stock price, while the lowest is $4.00 (+76.21%) and the highest is $24 (+957.27%).
Price Target: $8.82 (+288.55%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Compass Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 12 | 13 | 13 | 12 | 11 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 16 | 16 | 15 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $7 | Buy | Maintains | $7 | +208.37% | May 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $24 | Buy | Reiterates | $24 | +957.27% | May 22, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $6 | Buy | Maintains | $6 | +164.32% | May 10, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Maintains $12 → $8 | Buy | Maintains | $12 → $8 | +252.42% | May 6, 2026 |
Financial Forecast
Revenue This Year
1.56M
Revenue Next Year
38.85M
from 1.56M
Increased by 2,392.05%
EPS This Year
-0.43
from -0.42
EPS Next Year
-0.45
from -0.43
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 14.4M | 79.0M | ||||||
| Avg | 1.6M | 38.9M | ||||||
| Low | n/a | 7.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 4,967.7% | ||||||
| Avg | - | 2,392.0% | ||||||
| Low | - | 363.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.23 | -0.09 | ||||||
| Avg | -0.43 | -0.45 | ||||||
| Low | -0.58 | -0.80 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.